Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s Effects on Vaginal Atrophy in Postmenopausal Women
April 29, 2024 09:00 ET | Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, April 29, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
Azure logo new flatter arc-1200.png
Azure Biotech Announces Educational Initiative to Create Awareness of Unmet Women’s Menopausal Medical Issue
August 30, 2023 12:55 ET | Azure Biotech
RIVER VALE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Azure Biotech, Inc., a privately held women’s health company that is developing novel formulations of lasofoxifene for vulvovaginal atrophy (VVA),...
David Thompson, PhD to Lead Azure Biotech as President
March 08, 2016 10:32 ET | Azure Biotech, Inc.
GALES FERRY, CT--(Marketwired - March 08, 2016) - Azure Biotech, Inc. a private biotechnology company developing novel formulations of lasofoxifene announced today that David Thompson, PhD will...